A practical reference on peptide acylation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-30 and is reviewed periodically as new material appears.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
=== Other uses in science and technology === Rapid prototyping, a manufacturing and engineering process Rear projection effect, a film technique Red phosphorus, an allotrope of the element Rendezvous Point in Protocol Independent Multicast, a collection of network layer multicast routing protocols Reversed-phase chromatography, a laboratory technique Route Processor, a general-purpose CPU in some Cisco routers RP, a small rock climbing nut, named after Roland Pauligk RP-1, a rocket propellant RP-3, a British rocket projectile in World War II
=== Notable cases === In 1987, fifteen-year-old Mickey Hays, who had progeria, appeared along with Jack Elam in the documentary I Am Not a Freak. Elam and Hays first met during the filming of the 1986 film The Aurora Encounter, in which Hays was cast as an alien. The friendship that developed lasted until Hays died in 1992, on his 20th birthday. Elam said, "You know I've met a lot of people, but I've never met anybody that got next to me like Mickey." Harold Kushner, who among other things wrote the book When Bad Things Happen to Good People, had a son, Aaron, who died at the age of 14 in 1977 of progeria. Margaret Casey, a 29-year-old woman with progeria who was then believed to be the oldest survivor of the premature aging disease, died on Sunday, May 26, 1985. Casey, a freelance artist, was admitted to Yale New Haven Hospital on the night of May 25 with respiratory problems, which caused her death. Sam Berns was an American activist with the disease. He was the subject of the HBO documentary Life According to Sam. Berns also gave a TEDx talk titled "My Philosophy for a Happy Life" on December 13, 2013. Hayley Okines was an English progeria patient who spread awareness of the condition. Leon Botha, the South African painter and DJ who was known, among other things, for his work with the hip-hop duo Die Antwoord, lived with progeria. He died in 2011, aged 26. Alexandra Peraut is a Catalan girl with progeria; she has inspired the book Una nena entre vint milions ('A girl in 20 million'), a children's book to explain progeria to youngsters.
== How it works == Pyrolysis is the thermal decomposition of materials in an inert atmosphere or a vacuum. The sample is put into direct contact with a platinum wire, or placed in a quartz sample tube, and rapidly heated to 600–1000 °C. Depending on the application even higher temperatures are used. Three different heating techniques are used in actual pyrolyzers: Isothermal furnace, inductive heating (Curie Point filament), and resistive heating using platinum filaments. Large molecules cleave at their weakest bonds, producing smaller, more volatile fragments. These fragments can be separated by gas chromatography. Pyrolysis GC chromatograms are typically complex because a wide range of different decomposition products is formed. The data can either be used as fingerprint to prove material identity or the GC/MS data is used to identify individual fragments to obtain structural information. To increase the volatility of polar fragments, various methylating reagents can be added to a sample before pyrolysis. Besides the usage of dedicated pyrolyzers, pyrolysis GC of solid and liquid samples can be performed directly inside programmable temperature vaporizer (PTV) injectors that provide quick heating (up to 60 °C/s) and high maximum temperatures of 600-650 °C. This is sufficient for many pyrolysis applications. The main advantage is that no dedicated instrument has to be purchased and pyrolysis can be performed as part of routine GC analysis. In this case quartz GC inlet liners can be used.
== Economic impact == Migraines are a significant source of both medical costs and lost productivity. It has been estimated that migraine is the most costly headache disorder in the European Community, costing €50–111 billion per year in 2012. Most of the costs were due to lost work. As of 2017, in the United States, total costs were estimated at US$78 billion, with the cost per person multiple times bigger for those with chronic migraines. In those who do attend work during a migraine attack, effectiveness is decreased by around a third. Negative effects also frequently occur for a person's family.
== Taxonomy == Arnebia densiflora was first described by Carl Friedrich von Ledebour. It was first published in Flora Rossica Enumeratio sive Plantarum in Totivs Imperii Rossici Provinciis europaeis, Asiaticis, et americanis Hucusque Observatarum 3 (1.8): 140. 1847
Sources: en.wikipedia.org
Adenosine diphosphate ribose (ADPR) is an ester molecule formed into chains by the enzyme poly ADP ribose polymerase. ADPR is created from cyclic ADP-ribose (cADPR) by the CD38 enzyme using nicotinamide adenine dinucleotide (NAD+) as a cofactor. ADPR binds to and activates the TRPM2 ion channel. ADPR is the most potent agonist of the TRPM2 channel. cADPR also binds to TPRM2, and the action of both molecules is synergistic, with both molecules enhancing the action of the other molecule in activating the TRPM2 channel. Researchers are not sure how the Adenosine diphosphate reacts with the TRPM2 channel, but the ribose sugar may play a role in activating the TRPM2 ion channel. Researchers believe that co-targeting DNA-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 does not promote apoptosis or mitotic catastrophe of cancer cells after radiation.
After Ceaușescu was summarily executed, the National Salvation Front (FSN) quickly took power, promising free and fair elections within five months. Elected in a landslide the following May, the FSN reconstituted as a political party, installed a series of economic and democratic reforms, with further social policy changes being implemented by later governments. From that point on, Romania has become far more integrated with the West. Romania became a member of NATO and the European Union in 2004 and 2007, respectively.
== History == The first Canadian A&W restaurant opened in Winnipeg, Manitoba, in 1956. It spread across Canada with over 200 locations in the next ten years. The Canadian restaurants were part of the American chain until 1972 when they were sold to Unilever. In 1975, facing competition from the growing Canadian operations of McDonald's, the company launched an advertising campaign starring an orange-clad mascot, The Great Root Bear. The bear and the tuba jingle that accompanied him became a long-running campaign (the tune, entitled "Ba-Dum, Ba-Dum", was released as a single by Attic Records, credited to "Major Ursus", a play on Ursa Major or "great bear"). The famous Canadian composer and B.C. Hall of Fame winner Robert Buckley helped compose the song. The mascot was so successful that he was eventually adopted as the mascot by the American A&W chain as well. The famous tuba jingle was played by famed Vancouver jazz, classical and session trombonist Sharman King. In the early 1980s, the drive-in style of restaurant was phased out. It was replaced with a modern, pastel-coloured fast food outlet which included marginally healthier options. While the chain continued to open some standalone restaurants, A&W also aggressively pursued shopping mall locations, and as a result A&Ws are still commonly found in Canadian malls of various sizes.
The success of the submarine is inextricably linked to the development of the torpedo, invented by Robert Whitehead in 1866. His invention (essentially the same now as it was 140 years ago), allowed the submarine make the leap from novelty to a weapon of war. Prior to the development and miniaturization of sonar sensitive enough to track a submerged submarine, attacks were exclusively restricted to ships and submarines operating near or at the surface. Targeting of unguided torpedoes was initially done by eye, but by World War II analog targeting computers began to proliferate, being able to calculate basic firing solutions. Nonetheless, multiple "straight-running" torpedoes could be required to ensure a target was hit. With at most 20 to 25 torpedoes stored on board, the number of attacks a submarine could make was limited. To increase combat endurance starting in World War I submarines also functioned as submersible gunboats, using their deck guns against unarmed targets, and diving to escape and engage enemy warships. The initial importance of these deck guns encouraged the development of the unsuccessful Submarine Cruiser such as the French Surcouf and the Royal Navy's X1 and M-class submarines. With the arrival of anti-submarine warfare (ASW) aircraft, guns became more for defense than attack. A more practical method of increasing combat endurance was the external torpedo tube, loaded only in port. The ability of submarines to approach enemy harbours covertly led to their use as minelayers.
Nycomed, a Swiss drug company which manufactures Actovegin, claims it can be used for circulation and nutrition disturbances, skin grafting, burns, and wound-healing impairment. Actovegin has also been used as a performance enhancer. It has been investigated for use in treatment of polyneuropathy in diabetes, and for stroke. One study found that when tissues suffer from hypoxia caused circulation abnormalities, Actovegin helps capillaries improve circulation by enhancing the neogenic mechanism in blood vessels. Anaphylactic shock has been observed in at least one patient treated with actovegin. There are reports suggesting that Actovegin have ergogenic ability, however one small trial found no apparent benefit from short-term use. Two studies certified Actovegin to have an anti-inflammatory effect. One of the two studies certified Actovegin to reduce Progressive muscular atrophy-induced inflammation in human cells. Another study certified Actovegin to have a positive impact on the growth of muscle cells.
Sources: en.wikipedia.org
== History == In 1939, Martin Kamen and Samuel Ruben of the Radiation Laboratory at Berkeley began experiments to determine if any of the elements common in organic matter had isotopes with half-lives long enough to be of value in biomedical research. They synthesized 14C using the laboratory's cyclotron accelerator and soon discovered that the atom's half-life was far longer than had been previously thought. This was followed by a prediction by Serge A. Korff, then employed at the Franklin Institute in Philadelphia, that the interaction of thermal neutrons with 14N in the upper atmosphere would create 14C. It had previously been thought that 14C would be more likely to be created by deuterons interacting with 13C. At some time during World War II, Willard Libby, who was then at Berkeley, learned of Korff's research and conceived the idea that it might be possible to use radiocarbon for dating.
An insulin analogue (also called an insulin analog) is a type of medical insulin that has been modified to alter its pharmacokinetic properties while maintaining the same biological function as human insulin. These modifications are achieved through genetic engineering, which allows for changes in the amino acid sequence of insulin to optimize its absorption, distribution, metabolism, and excretion (ADME) characteristics. All insulin analogues work by enhancing glucose uptake in tissues and reducing glucose production by the liver. They are prescribed for conditions such as type 1 diabetes, type 2 diabetes, gestational diabetes, and diabetes-related complications such as diabetic ketoacidosis. Additionally, insulin is sometimes administered alongside glucose to treat elevated blood potassium levels (hyperkalemia). Insulin analogues are classified based on their duration of action. Short-acting (bolus) insulin analogues, such as insulin lispro, insulin aspart, and insulin glulisine, have been designed to be absorbed quickly, mimicking the natural insulin response after meals. Long-acting (basal) insulin analogues, including insulin glargine, insulin detemir, and insulin degludec, provide a sustained release of insulin to maintain basal blood glucose levels over an extended period. These modifications enhance the predictability of insulin therapy and reduce the risk of hypoglycemia compared to regular human insulin. Lispro, the first insulin analogue, was approved in 1996. This was followed by an influx of new analogues with differing pharmacokinetic properties.
On 10 September 2008, Matthew Bryza said before the Commission on Security and Cooperation in Europe, "But there's much more to the story than that. The conflict certainly did not begin on August 7th. [...] Already we saw that the Russian peacekeepers were playing a role in providing a shield, we believe, to the South Ossetians who were shooting at the Georgian positions." After the war, Irakli Okruashvili, who served as Minister of Defence of Georgia, claimed that he and President Saakashvili had prepared plans to retake South Ossetia and Abkhazia in 2005. The alleged original plans intended a two-pronged offensive into South Ossetia. Saakashvili believed that a Russian response would be checked by the United States through diplomacy, so he did not order the taking of the Roki Tunnel. Georgian forces raced to contain the Russian forces, but were "outmaneuvered by the Russians." Okruashvili said that Russian response would be "inevitable" as after 2006, Russians "repositioned and improved their military infrastructure in the North Caucasus, Abkhazia, and South Ossetia." The Georgian Army could have defended a few major towns from the Russians, but President Saakashvili "let the Russians in to avoid criticism and appear more of a victim". In September 2008, Matthew Bryza said there was no disagreement between the intercepted phone conversations (which were presented as evidence of Russian invasion on 7 August) and August 7 statements of Georgian officials made during the phone calls between Bryza and Georgians.
== Limits of reversal == Most tissues and organs of the body can survive clinical death for considerable periods. Blood circulation can be stopped in the entire body below the heart for at least 30 minutes, with injury to the spinal cord being a limiting factor. Detached limbs may be successfully reattached after 6 hours of no blood circulation at warm temperatures. Bone, tendon, and skin can survive as long as 8 to 12 hours. The brain, however, appears to accumulate ischemic injury faster than any other organ. Without special treatment after circulation is restarted, full recovery of the brain after more than 3 minutes of clinical death at normal body temperature is rare. Usually brain damage or later brain death results after longer intervals of clinical death even if the heart is restarted and blood circulation is successfully restored. Brain injury is therefore the chief limiting factor for recovery from clinical death. Although loss of function is almost immediate, there is no specific duration of clinical death at which the non-functioning brain clearly dies. The most vulnerable cells in the brain, CA1 neurons of the hippocampus, are fatally injured by as little as 10 minutes without oxygen. However, the injured cells do not actually die until hours after resuscitation. This delayed death can be prevented in vitro by a simple drug treatment even after 20 minutes without oxygen. In other areas of the brain, viable human neurons have been recovered and grown in culture hours after clinical death.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.